Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 1
Submit an article Journal homepage
946
Views
5
CrossRef citations to date
0
Altmetric
Articles

Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator–controlled VOYAGE 1/2 trials

Sang Woong Youna Department of Dermatology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam, KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5602-3530View further author information
ORCID Icon,
Dae Young Yub Medical Affairs, Janssen Korea Ltd., Seoul, Korea;c Department of Public Health, Korea University College of Medicine, Seoul, KoreaORCID Iconhttps://orcid.org/0000-0003-1091-5792View further author information
ORCID Icon,
Tae Yoon Kimd Department of Dermatology, Catholic University of Korea Seoul St. Mary’s Hospital, Seoul, KoreaView further author information
,
Byung Soo Kime Department of Dermatology, Pusan National University School of Medicine, Busan, KoreaORCID Iconhttps://orcid.org/0000-0003-0054-8570View further author information
ORCID Icon,
Seung Chul Leef Department of Dermatology, Chonnam National University Hospital, Gwangju, KoreaView further author information
,
Jeung Hoon Leeg Department of Dermatology, Chungnam National University Hospital, Daejeon, KoreaView further author information
,
Yong-Beom Choeh Department of Dermatology, Konkuk University School of Medicine, Seoul, KoreaView further author information
,
Joo-Heung Leei Department of Dermatology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, KoreaView further author information
,
Jee-Ho Choij Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, KoreaView further author information
,
Joo Young Rohk Department of Dermatology, Gachon University College of Medicine, Gil Medical Center, Incheon, KoreaView further author information
,
Seong Jin Jol Department of Dermatology, Seoul National University College of Medicine, Seoul, KoreaView further author information
,
Eun-So Leem Department of Dermatology, Ajou University Hospital, Suwon, KoreaView further author information
,
Min Kyung Shinn Department of Dermatology, Kyunghee University Medical Center, Seoul, KoreaView further author information
,
Min-Geol Leeo Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, KoreaView further author information
,
Jingzhi Jiangp Janssen Research & Development LLC, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0002-4662-3268View further author information
ORCID Icon &
YoungJa Leeb Medical Affairs, Janssen Korea Ltd., Seoul, KoreaView further author information
 show all
Pages 535-541 | Received 15 Apr 2020, Accepted 13 May 2020, Published online: 27 May 2020

References

  • Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
  • Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014;24(5):523–532.
  • Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J Cutan Med Surg. 2009;13 Suppl 2 (Suppl 2):S67–S76.
  • Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040.
  • Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
  • Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
  • Reich K, Song M, Li S, et al. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019;46(12):1141–1152.
  • Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–667.
  • Wang TS, Hsieh CF, Tsai TF. Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: a nationwide, population-based observational study in Taiwan. J Dermatol Sci. 2016;84(3):340–345.
  • Oh EH, Ro YS, Kim JE. Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study. J Dermatol. 2017;44(6):621–629.
  • Kim J, Oh CH, Jeon J, et al. Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets. J Invest Dermatol. 2016;136(1):161–172.
  • Lew W, Lee E, Krueger JG. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol. 2004;150(4):668–676.
  • Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.
  • Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
  • Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–163.
  • Ohtsuki M, Morita A, Abe M, the ERASURE Study Japanese subgroup, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039–1046.
  • Ohtsuki M, Kubo H, Morishima H, et al. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062.
  • Kemény L, Berggren L, Dossenbach M, et al. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. J Dermatolog Treat. 2019;30(1):19–26.
  • Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
  • Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
  • Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.